Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Usana Health Sciences (USNA) Finished Goods (2016 - 2022)

Usana Health Sciences has reported Finished Goods over the past 12 years, most recently at $51.5 million for Q3 2022.

  • Quarterly Finished Goods fell 4.14% to $51.5 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was $51.5 million through Jul 2022, down 4.14% year-over-year, with the annual reading at $58.5 million for FY2022, 12.54% up from the prior year.
  • Finished Goods was $51.5 million for Q3 2022 at Usana Health Sciences, down from $57.3 million in the prior quarter.
  • Over five years, Finished Goods peaked at $58.5 million in Q1 2022 and troughed at $36.6 million in Q1 2020.
  • The 5-year median for Finished Goods is $48.7 million (2018), against an average of $47.8 million.
  • Year-over-year, Finished Goods soared 42.23% in 2018 and then plummeted 30.13% in 2020.
  • A 5-year view of Finished Goods shows it stood at $48.0 million in 2018, then dropped by 14.69% to $40.9 million in 2019, then increased by 15.12% to $47.1 million in 2020, then rose by 16.78% to $55.0 million in 2021, then fell by 6.3% to $51.5 million in 2022.
  • Per Business Quant, the three most recent readings for USNA's Finished Goods are $51.5 million (Q3 2022), $57.3 million (Q2 2022), and $58.5 million (Q1 2022).